HIV patients with high liver enzymes who lost enough belly fat from tesamorelin were more than twice as likely to have their ALT levels return to normal compared to those who didn't lose much fat.

HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.

HIV patients with high liver enzymes who lost visceral fat from the drug kept their liver enzyme levels improved for a full year even after stopping the drug and some fat coming back.

HIV patients with high ALT who lost visceral fat had a 35% chance of normalizing their ALT levels after 6 months, compared to 18% who didn't lose fat, showing a clear benefit.